Wells Fargo & Company Forecasts Strong Price Appreciation for Cooper Companies (NASDAQ:COO) Stock

Cooper Companies (NASDAQ:COO) had its price target hoisted by research analysts at Wells Fargo & Company from $72.00 to $82.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the medical device company’s stock. Wells Fargo & Company‘s target price points to a potential upside of 0.74% from the stock’s current price.

Several other analysts have also recently weighed in on COO. JPMorgan Chase & Co. lifted their price objective on Cooper Companies from $66.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday. Robert W. Baird lifted their price target on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Cooper Companies in a research note on Monday, December 1st. Needham & Company LLC reiterated a “buy” rating and issued a $100.00 price objective (up previously from $94.00) on shares of Cooper Companies in a report on Friday. Finally, KeyCorp restated a “sector weight” rating on shares of Cooper Companies in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and an average price target of $90.31.

Cooper Companies Stock Up 5.7%

Shares of NASDAQ COO opened at $81.40 on Friday. The firm has a fifty day simple moving average of $72.29 and a two-hundred day simple moving average of $71.67. Cooper Companies has a 12 month low of $61.78 and a 12 month high of $101.53. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $16.18 billion, a PE ratio of 43.30, a price-to-earnings-growth ratio of 2.00 and a beta of 1.05.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.01%. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the firm posted $1.04 EPS. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities analysts expect that Cooper Companies will post 3.98 earnings per share for the current year.

Cooper Companies announced that its board has approved a stock buyback program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Cooper Companies

In related news, Director Lawrence Erik Kurzius purchased 2,000 shares of Cooper Companies stock in a transaction dated Monday, September 29th. The stock was purchased at an average cost of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the acquisition, the director directly owned 5,777 shares of the company’s stock, valued at $395,089.03. The trade was a 52.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.98% of the stock is owned by insiders.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors have recently modified their holdings of the business. Allworth Financial LP increased its holdings in Cooper Companies by 23.9% in the 3rd quarter. Allworth Financial LP now owns 1,188 shares of the medical device company’s stock worth $81,000 after buying an additional 229 shares in the last quarter. IFP Advisors Inc boosted its holdings in shares of Cooper Companies by 2,647.8% during the 3rd quarter. IFP Advisors Inc now owns 632 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 609 shares during the last quarter. Swiss Life Asset Management Ltd grew its stake in shares of Cooper Companies by 63.9% in the third quarter. Swiss Life Asset Management Ltd now owns 49,409 shares of the medical device company’s stock worth $3,387,000 after acquiring an additional 19,264 shares during the period. CIBC Bancorp USA Inc. purchased a new position in shares of Cooper Companies during the third quarter valued at approximately $1,887,000. Finally, Bell Investment Advisors Inc lifted its position in Cooper Companies by 106.3% during the third quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 219 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.